These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 30637614)
41. Interaction between Neuromelanin and Alpha-Synuclein in Parkinson's Disease. Xu S; Chan P Biomolecules; 2015 Jun; 5(2):1122-42. PubMed ID: 26057626 [TBL] [Abstract][Full Text] [Related]
42. Selective imaging of internalized proteopathic α-synuclein seeds in primary neurons reveals mechanistic insight into transmission of synucleinopathies. Karpowicz RJ; Haney CM; Mihaila TS; Sandler RM; Petersson EJ; Lee VM J Biol Chem; 2017 Aug; 292(32):13482-13497. PubMed ID: 28611062 [TBL] [Abstract][Full Text] [Related]
43. The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration. Mahul-Mellier AL; Burtscher J; Maharjan N; Weerens L; Croisier M; Kuttler F; Leleu M; Knott GW; Lashuel HA Proc Natl Acad Sci U S A; 2020 Mar; 117(9):4971-4982. PubMed ID: 32075919 [TBL] [Abstract][Full Text] [Related]
44. The Interplay between Alpha-Synuclein Clearance and Spreading. Lopes da Fonseca T; Villar-Piqué A; Outeiro TF Biomolecules; 2015 Apr; 5(2):435-71. PubMed ID: 25874605 [TBL] [Abstract][Full Text] [Related]
45. Metabotropic glutamate receptor 5 inhibits α-synuclein-induced microglia inflammation to protect from neurotoxicity in Parkinson's disease. Zhang YN; Fan JK; Gu L; Yang HM; Zhan SQ; Zhang H J Neuroinflammation; 2021 Jan; 18(1):23. PubMed ID: 33461598 [TBL] [Abstract][Full Text] [Related]
46. C-terminal truncation exacerbates the aggregation and cytotoxicity of α-Synuclein: A vicious cycle in Parkinson's disease. Ma L; Yang C; Zhang X; Li Y; Wang S; Zheng L; Huang K Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3714-3725. PubMed ID: 30290273 [TBL] [Abstract][Full Text] [Related]
47. Therapeutic functions of astrocytes to treat α-synuclein pathology in Parkinson's disease. Yang Y; Song JJ; Choi YR; Kim SH; Seok MJ; Wulansari N; Darsono WHW; Kwon OC; Chang MY; Park SM; Lee SH Proc Natl Acad Sci U S A; 2022 Jul; 119(29):e2110746119. PubMed ID: 35858361 [TBL] [Abstract][Full Text] [Related]
48. Cysteine cathepsins are essential in lysosomal degradation of α-synuclein. McGlinchey RP; Lee JC Proc Natl Acad Sci U S A; 2015 Jul; 112(30):9322-7. PubMed ID: 26170293 [TBL] [Abstract][Full Text] [Related]
49. Lysosomal response in relation to α-synuclein pathology differs between Parkinson's disease and multiple system atrophy. Puska G; Lutz MI; Molnar K; Regelsberger G; Ricken G; Pirker W; Laszlo L; Kovacs GG Neurobiol Dis; 2018 Jun; 114():140-152. PubMed ID: 29505813 [TBL] [Abstract][Full Text] [Related]
50. Alpha-Synuclein: The Interplay of Pathology, Neuroinflammation, and Environmental Factors in Parkinson's Disease. He S; Zhong S; Liu G; Yang J Neurodegener Dis; 2020; 20(2-3):55-64. PubMed ID: 33465773 [TBL] [Abstract][Full Text] [Related]
51. Alpha-Synuclein as a Prominent Actor in the Inflammatory Synaptopathy of Parkinson's Disease. Cardinale A; Calabrese V; de Iure A; Picconi B Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34204581 [TBL] [Abstract][Full Text] [Related]
52. Loss of functional alpha-synuclein: a toxic event in Parkinson's disease? Kanaan NM; Manfredsson FP J Parkinsons Dis; 2012; 2(4):249-67. PubMed ID: 23938255 [TBL] [Abstract][Full Text] [Related]
53. Accumulation of alpha-synuclein within the liver, potential role in the clearance of brain pathology associated with Parkinson's disease. Reyes JF; Ekmark-Léwen S; Perdiki M; Klingstedt T; Hoffmann A; Wiechec E; Nilsson P; Nilsson KPR; Alafuzoff I; Ingelsson M; Hallbeck M Acta Neuropathol Commun; 2021 Mar; 9(1):46. PubMed ID: 33743820 [TBL] [Abstract][Full Text] [Related]
54. The misfolding mystery: α-synuclein and the pathogenesis of Parkinson's disease. Negi S; Khurana N; Duggal N Neurochem Int; 2024 Jul; 177():105760. PubMed ID: 38723900 [TBL] [Abstract][Full Text] [Related]
55. Ciita Regulates Local and Systemic Immune Responses in a Combined rAAV-α-synuclein and Preformed Fibril-Induced Rat Model for Parkinson's Disease. Fredlund F; Jimenez-Ferrer I; Grabert K; Belfiori LF; Luk K; Swanberg M J Parkinsons Dis; 2024; 14(4):693-711. PubMed ID: 38728204 [TBL] [Abstract][Full Text] [Related]
56. Lycorine, a natural alkaloid, promotes the degradation of alpha-synuclein via PKA-mediated UPS activation in transgenic Parkinson's disease models. Zhu Q; Zhuang XX; Chen JY; Yuan NN; Chen Y; Cai CZ; Tan JQ; Su HX; Lu JH Phytomedicine; 2021 Jul; 87():153578. PubMed ID: 34038839 [TBL] [Abstract][Full Text] [Related]
57. Tetramethylpyrazine Analogue T-006 Promotes the Clearance of Alpha-synuclein by Enhancing Proteasome Activity in Parkinson's Disease Models. Zhou H; Shao M; Guo B; Li C; Lu Y; Yang X; ShengnanLi ; Li H; Zhu Q; Zhong H; Wang Y; Zhang Z; Lu J; Lee SM Neurotherapeutics; 2019 Oct; 16(4):1225-1236. PubMed ID: 31313223 [TBL] [Abstract][Full Text] [Related]
58. Effects of innate immune receptor stimulation on extracellular α-synuclein uptake and degradation by brain resident cells. Kim C; Kwon S; Iba M; Spencer B; Rockenstein E; Mante M; Adame A; Shin SJ; Fields JA; Rissman RA; Lee SJ; Masliah E Exp Mol Med; 2021 Feb; 53(2):281-290. PubMed ID: 33594256 [TBL] [Abstract][Full Text] [Related]
59. Protein tyrosine phosphatase receptor type O serves as a key regulator of insulin resistance-induced α-synuclein aggregation in Parkinson's disease. Tan S; Chi H; Wang P; Zhao R; Zhang Q; Gao Z; Xue H; Tang Q; Li G Cell Mol Life Sci; 2024 Sep; 81(1):403. PubMed ID: 39276174 [TBL] [Abstract][Full Text] [Related]
60. Distinct alpha-Synuclein species induced by seeding are selectively cleared by the Lysosome or the Proteasome in neuronally differentiated SH-SY5Y cells. Pantazopoulou M; Brembati V; Kanellidi A; Bousset L; Melki R; Stefanis L J Neurochem; 2021 Mar; 156(6):880-896. PubMed ID: 32869336 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]